Parvovirus cancer therapy and combination with chemotherapy

US8414883B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Jean Rommelaere · Heidelberg, DE
• Zahari Raykov · Heidelberg, DE
• Joerg Schlehofer · Leimen, DE
• Irina Kiprijanova · Heidelberg, DE
• Tanja Heimberger · Coburg, DE
• Assia Angelova · Heidelberg, DE
• Karsten Geletneky · Heidelberg, DE
• Marc Aprahamian · Heidelberg, DE

Key dates

• Filing date: Dec 23, 2008
• Grant date: Apr 9, 2013
• Expiry date: Dec 23, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14032
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.